Skip to main content

Table 2 Results of ATRX and IDH mutation status stratified by histological diagnosis

From: ATRX immunostaining predicts IDH and H3F3A status in gliomas

Tumor

WHO Grade

ATRX loss/retention (n)a

IDH mutated/WT (n)a

IDH mutant & ATRX loss/retention (n)a

H3F3A mutant & ATRX loss/retention (n)a

Diffuse Astrocytoma

 

136/120 (53 %)

156/113 (42 %)

116/20 (85 %)

 

 - Low grade

II

72/49 (59 %)

86/44 (66 %)

62/12 (84 %)

 

 - Anaplastic

III

64/71 (47 %)

70/69 (50 %)

52/10 (84 %)

4/0 (100 %)

Oligoastrocytoma

 

23/48 (32 %)

66/6 (92 %)

23/42 (35 %)

 

 - Low grade

II

8/31 (21 %)

36/3 (92 %)

8/28 (23 %)

 

 - Anaplastic

III

15/17 (47 %)

30/3 (91 %)

15/14 (52 %)

 

Oligodendroglioma

 

1/79 (1 %)

81/2 (98 %)

1/77 (1 %)

 

 - Low grade

II

0/33 (0 %)

35/0 (100 %)

0/33 (0 %)

 

 - Anaplastic

III

1/46 (2 %)

46/2 (96 %)

1/44 (2 %)

 

Glioblastoma

IV

47/260 (15 %)

38/295 (11 %)

33/9 (79 %)

5/7 (42 %)

 - Primary

IV

27/215 (11 %)

19/224 (7 %)

17/3 (89 %)

5/7 (42 %)

 - Secondary

IV

16/14 (53 %)

19/11 (63 %)

14/5 (78 %)

 

 - With oligodendroglial component

IV

3/10 (23 %)

4/8 (33 %)

3/1 (75 %)

 

 - With PNET component

IV

0/1 (0 %)

0/1 (0 %)

  

 - Gliosarcoma

IV

0/6 (0 %)

0/6 (0 %)

  

Ependymoma

 

0/93 (0 %)

0/98 (0 %)

  

 - Low grade

II

0/43 (0 %)

0/41 (0 %)

  

 - Anaplastic

III

0/23 (0 %)

0/23 (0 %)

  

 - Myxopapillary

I

0/18 (0 %)

0/24 (0 %)

  

 - Subependymoma

I

0/9 (0 %)

0/10 (0 %)

  

Pilocytic astrocytoma

I

0/57 (0 %)

0/57 (0 %)

  

 - Pilomyxoid

II

0/1 (0 %)

0/1 (0 %)

  

 - Anaplastic

III

1/1 (50 %)

0/2 (0 %)

  
  1. aValues in brackets show the percentage of tumors with ATRX loss within the respective sample cohort. For Ependymoma and pilocytic, pilomyxoid and anaplastic pilocytic astrocytoma ony the results of IDH1 (R132)-IHC were available